IL10 and breast cancer: In contrast, inhibiting TGF‐β or IL10 significantly suppresses this recruitment.[112] Thus, TGF‐β inhibitor is a promising drug for enhancing immunotherapy efficacy in BC.[113] The evidence suggests that the TGF‐β pathway plays a critical role in bladder and prostate development, while also being involved in the progression of BC and PCa.